Ascendis Pharma AS (NASDAQ:ASND) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “
Several other equities research analysts also recently issued reports on ASND. TheStreet upgraded shares of Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Leerink Swann restated a “buy” rating on shares of Ascendis Pharma AS in a research report on Friday, September 2nd. Finally, Wedbush assumed coverage on shares of Ascendis Pharma AS in a research report on Monday, September 26th. They set an “outperform” rating and a $34.00 price objective for the company.
Shares of Ascendis Pharma AS (NASDAQ:ASND) opened at 19.99 on Monday. The company’s market capitalization is $503.61 million. The company’s 50-day moving average price is $19.30 and its 200-day moving average price is $16.14. Ascendis Pharma AS has a 52-week low of $11.92 and a 52-week high of $21.70.
Ascendis Pharma AS (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. Equities research analysts forecast that Ascendis Pharma AS will post ($3.14) EPS for the current fiscal year.
About Ascendis Pharma AS
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma AS and related companies with MarketBeat.com's FREE daily email newsletter.